Effect of Liver MSCs in Blood of Patients With Liver Disease. (CIRRHOTIQUE01)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Status

Completed

Conditions

Decompensated Cirrhosis

Study type

Observational

Funder types

Other

Identifiers

NCT03632148

2017/23JUI/331

Details and patient eligibility

About

Liver MSCs or Adult Derived Human Liver Stem/progenitor Cells (ADHLSCs) infusions are currently being developed as a therapeutic medicinal product for the treatment of different liver defects. Nevertheless, a main concern for clinicians and health authorities is the risk of therapy-induced thrombosis, which has been reported in several patients after intravenous infusion. Previous studies showed in fact that most MSCs express a procoagulant activity. ADHLSCs could be used to treat acute de-compensated cirrhotic patients due to their immunomodulatory and anti-fibrotic effects. However in these patients, disturbances of coagulation and haemostasis are common and result in profound haemostatic alterations that can lead to thrombosis as well as to bleeding complications. The aim of this study is to evaluate the effect of ADHLSCs in cirrhotic blood compared to control blood.

Enrollment

9 patients

Sex

All

Ages

12 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria